Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients with Neuroendocrine Neoplasms Recruiting

2024-516156-18-00 Neuroendocrine neoplasms 4 2023-01-17
Master Protocol for Crizotinib Continuation Sub-Studies Recruiting

2024-511128-15-00 This Master Protocol for Crizotinib Continuation Sub-St 6 2023-01-17
VEMURAFENIB PLUS RITUXIMAB AS A CHEMOTHERAPY-FREE ALTERNATIVE TO CLADRIBINE FOLLOWED BY MRD-GUIDED RITUXIMAB IN FRONT-LINE HAIRY CELL LEUKEM… Recruiting

2024-520119-41-00 Previously untreated patients with diagnosis of HCL 4 2023-01-15
Phase 1b/2a Study to Evaluate CC-92480 (BMS-986348) in Combination with Other Treatments in Relapsed or Refractory Multiple Myeloma Recruiting

2023-509384-25-00 Relapsed or Refractory Multiple Myeloma (RRMM) 9 2022-12-30
A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokine… Recruiting

2023-506818-45-00 Solid tumors that have a high incidence of Homologous R 7 2022-12-13
OFOBA : Opioid-Free versus Opioid-Based Anaesthesia for free-flap reconstruction surgery of the breast: A phase III multicentric randomized… Recruiting

2024-513308-32-00 Anaesthesia during free flap reconstruction surgery of 5 2022-12-07
International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents Recruiting

2022-500783-35-00 Acute Myeloid Leukemia 5 2022-12-06
A phase 2 trial on propranolol in combination with pembrolizumab in advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma Recruiting

2024-513727-16-00 Advanced Angiosarcoma and Undifferentiated Pleomorphic 4 2022-12-05
A multicenter phase 1/2 study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas Recruiting

2024-514826-22-00 Part A: Patients with advanced solid tumors or lymphoma 7 2022-12-05
Phase I Study of PM534 Administered to Patients with Advanced Solid Tumors Recruiting

2024-513056-15-00 Advanced Solid Tumors 7 2022-12-01
Clinical study to test the safety, tolerance and preliminary efficacy of oral ITF3756 administered alone or in combination with an anti-prot… Recruiting

2022-501089-22-00 Advanced solid tumors 1 2022-11-29
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells Recruiting

2023-507041-28-00 Solid and Hematological Malignancies 4 2022-11-28
A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting

2024-514180-25-00 unresectable or metastatic HER2+ colorectal cancer 5 2022-11-21
A First-in-Human Dose Escalation Study of JNJ-79635322, in Participants with Relapsed or Refractory Multiple Myeloma or Previously Treated A… Recruiting

2023-503679-12-00 Relapsed or Refractory Multiple Myeloma 1 2022-11-21
CO43923 Master Protocol: A Study Evaluating the Safety and Efficacy of Multiple Treatments in Patients with Multiple Myeloma CO43923 Substud… Recruiting

2023-504484-16-00 Multiple Myeloma (MM) 9 2022-11-18
MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dex… Recruiting

2024-514139-50-00 Multiple myeloma 5 2022-11-14
Phase 1/1b study to assess the drug OBT076 in patients with recurrent and/or metastatic CD205-positive solid tumors Recruiting

2024-511884-27-00 CD205+ve recurrent and/or metastatic tumor types includ 3 2022-11-09
Evaluation of metformin effect on the fertility of women treated with 131Ifor thyroid cancer Recruiting

2024-518352-23-00 papillary thyroid carcinoma 5 2022-11-09
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination with Che… Recruiting

2023-504264-41-00 CD20 positive B-Cell Non-Hodgkin Lymphoma (NHL) 9 2022-11-04
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors… Recruiting

2024-514266-39-00 Advanced Non-Small Cell Lung Cancer (NSCLC) and Other S 7 2022-11-03
A continued study in patients with Hematologic Cancers previously treated with Tafasitamab. Recruiting

2022-500765-27-00 Hematologic malignancies 5 2022-11-03
Phase I/II dose escalation trial of radiodynamic therapy (RDT) with 5-Aminolevulinic acid in patients with first recurrence of glioblastoma Recruiting

2024-517651-12-00 recurrent glioblastoma 9 2022-10-28
First-in-Human Study of RLY-2608 in Advanced Breast Cancer and Other Solid Tumors. Recruiting

2022-500264-35-00 Advanced solid tumor with a PIK3CA mutation in blood an 1 2022-10-28
A long-term monitoring study of patients suffering from a malignant neoplasm of the central nervous system previously treated with hematopoi… Recruiting

2024-516211-25-00 Glioblastoma multiforme (GBM) 9 2022-10-27